KARD
Kardigan, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.85
+0.53%Income statement
| Metric | 2025 |
|---|---|
| Revenue | |
| Total Revenue | — |
| Cost of Revenue | — |
| Gross Profit | — |
| Operating Expenses | |
| R&D Expense | 153.1M |
| SG&A Expense | 48.8M |
| General & Admin Expense | 48.8M |
| Selling & Marketing Expense | — |
| Other Expenses | — |
| Total Operating Expenses | 201.8M |
| Cost and Expenses | 201.8M |
| Operating Income (EBIT) | (201.8M) |
| Non-Operating | |
| Interest Income | 6.8M |
| Interest Expense | — |
| Net Interest Income | 6.8M |
| Other Non-Op Income/Expense | 5.4M |
| Non-Operating Income (excl Interest) | — |
| EBT (Pre-Tax Income) | (196.5M) |
| Income Tax Expense | (4.5M) |
| Bottom Line | |
| Net Income | (191.9M) |
| Earnings from Cont. Ops | (191.9M) |
| Earnings from Discont. Ops | — |
| Bottom Line Net Income | (191.9M) |
| Per Share | |
| Basic EPS | ($3.20) |
| Diluted EPS | ($3.20) |
| Revenue Per Share | $0.00 |
| Shares | |
| Basic Shares Outstanding | 60.0M |
| Diluted Shares Outstanding | 60.0M |
| Profitability Metrics | |
| EBITDA | (196.0M) |
| D&A | 5.8M |
| EBIT | (201.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026